Tribunal Grants Bulk Drug Manufacturers Eligibility for Benefits Under 2006 Notification; Nevirapine and Stavudine Qualified.

The Tribunal ruled in favor of the appellants, manufacturers of bulk drugs, granting them eligibility for benefits under Notification No. 4/2006-C.E., dated 1-3-2006. It determined that the drugs Nevirapine and Stavudine, cleared for formulation manufacturing, qualified under the specified category of the Notification. The Tribunal set aside the impugned orders, emphasizing that bulk drugs should be considered as drugs for the Notification's purposes, aligning with legal precedents and specific entries in the Notification. This decision entitles the appellants to the benefits, as their products fell within the specified category.

---

---

Issues:
Interpretation of Notification No. 4/2006-C.E., dated 1-3-2006 regarding eligibility for benefits under Category (A) to Sl. No. 47 for manufacturers of drugs.

Detailed Analysis:

1. Issue of Eligibility under Notification: The appellants, manufacturers of drugs, claimed eligibility under Category (A) to Sl. No. 47 of Notification No. 4/2006-C.E., dated 1-3-2006. The Department contended that the items manufactured by the appellants were covered under Sl. No. 47(B) as bulk drugs, requiring specific conditions to be followed. The appellants argued that the items, Nevirapine and Stavudine, were cleared to another company for formulation manufacturing, thus not resulting in revenue loss. The Tribunal considered the specific entries of the items in List 3 of Notification No. 21/2002-Cus., dated 1-3-2002, and held that the appellants were eligible for the benefit of the Notification as the items were bulk drugs falling under the specified category.

2. Interpretation of Legal Precedents: The appellants relied on legal precedents, including the case of M/s. Burroughs Wellcome (I) Ltd. v. CCE and Cipla Ltd. v. CC, Chennai, to support their argument that bulk drugs should be considered as drugs for the purpose of the Notification. The Tribunal noted that the items cleared by the appellants were accounted for at nil rate of duty by the recipient company, which used them for manufacturing formulations/medicines specified in the Notification. The Tribunal emphasized that the term "drug" should include bulk drugs and formulations as per relevant regulations, thereby entitling the appellants to the benefit of the Notification.

3. Comparison with Similar Cases: The Tribunal compared the present case with the case of M/s. Burroughs Wellcome (I) Ltd., where the issue revolved around the entitlement of bulk drugs for exemption under a specific Notification. The Tribunal found similarities in the facts and legal provisions, leading to the conclusion that the benefit of the Notification should be extended to the appellants based on the specific entries of the items in the relevant Notification.

4. Final Decision: After considering the arguments from both sides and analyzing the legal provisions and precedents, the Tribunal set aside the impugned orders, ruling in favor of the appellants. The Tribunal concluded that the appellants, being manufacturers of bulk drugs falling under the specified category, were entitled to the benefits under Notification No. 4/2006-C.E., dated 1-3-2006. The decision was based on the specific entries of the items in the Notification and the interpretation of relevant legal provisions and precedents.

This detailed analysis of the judgment highlights the key issues, legal interpretations, comparisons with similar cases, and the final decision reached by the Tribunal in favor of the appellants.

---